SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3

Genes Chromosomes and Cancer

Volumn 51, Issue 8, 2012, Pages 756-767

  Nowak, Daniel ^a   Klaumuenzer, Marion ^a   Hanfstein, Benjamin ^a   Mossner, Maximilian ^a   Nolte, Florian ^a   Nowak, Verena ^a   Oblaender, Julia ^a   Hecht, Anna ^a   Hütter, Gero ^a   Ogawa, Seishi ^b   Kohlmann, Alexander ^c   Haferlach, Claudia ^c   Schlegelberger, Brigitte ^d   Braess, Jan ^e   Seifarth, Wolfgang ^a   Fabarius, Alice ^a   Erben, Philipp ^a   Saussele, Susanne ^a   Müller, Martin C ^a   Reiter, Andreas ^a   Buechner, Thomas ^f   Weiss, Christel ^a   Hofmann, Wolf Karsten ^a   Lengfelder, Eva ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TOKYO   (Japan)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GENOMIC DNA; MICRORNA;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHROMOSOME 1Q; COPY NUMBER ALTERATION; COPY NUMBER VARIATION; DNA DETERMINATION; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE TRANSLOCATION; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DELETION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; STATISTICS, NONPARAMETRIC; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84861717511     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21961     Document Type: Article

References (32)

1. Ades L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P. 2010. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: The European APL Group experience. Blood 115: 1690-1696.
2. Akagi T, Shih LY, Kato M, Kawamata N, Yamamoto G, Sanada M, Okamoto R, Miller CW, Liang DC, Ogawa S, Koeffler HP. 2009. Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 113: 1741-1748.
3. Barbouti A, Stankiewicz P, Nusbaum C, Cuomo C, Cook A, Hoglund M, Johansson B, Hagemeijer A, Park SS, Mitelman F, Lupski JR, Fioretos T. 2004. The breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats. Am J Hum Genet 74: 1-10.
4. Barragan E, Montesinos P, Camos M, Gonzalez M, Calasanz MJ, Roman-Gomez J, Gomez-Casares MT, Ayala R, Lopez J, Fuster O, Colomer D, Chillon C, Larrayoz MJ, Sanchez-Godoy P, Gonzalez-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA. 2011. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica 17: 17.
5. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. 2003. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642-4649.
6. de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, Esteve J, Bergua JM, Milone G, Deben G, Rivas C, Gonzalez M, Tormo M, Diaz-Mediavilla J, Gonzalez JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. 2008. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111: 3395-3402.
7. Feng GS, Ouyang YB, Hu DP, Shi ZQ, Gentz R, Ni J. 1996. Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway. J Biol Chem 271: 12129-12132.
8. Gray RJ. 1988. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat 16: 1141-1154.
9. Iacobucci I, Ottaviani E, Salmi F, Guadagnuolo V, Testoni N, Lonetti A, Papayannidis C, Paolini S, Cilloni D, Malagola M, Baldazzi C, Messa F, Candoni A, Arruga F, Visani G, Saglio G, Rondoni M, Pane F, Khizer HS, Baccarani M, Martinelli G, Lo Coco F. 2009. Genome-wide analysis by high-resolution SNP array identifies novel genomic alterations in acute promyelocytic leukemia (APL). Blood 114: Abstract 167.
10. Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, Le Beau MM, Kogan SC. 2010. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med 207: 2581-2594.
11. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
12. Kim HT. 2007. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 13( 2, Part 1): 559-565.
13. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H, Staib P, Heyll A, Seifarth W, Saussele S, Fonatsch C, Gassmann W, Ludwig WD, Hochhaus A, Beelen D, Aul C, Sauerland MC, Heinecke A, Hehlmann R, Wormann B, Hiddemann W, Buchner T. 2000. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14: 1362-1370.
14. Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, Ludwig WD, Staib P, Aul C, Gruneisen A, Kern W, Reichle A, Serve H, Berdel WE, Braess J, Spiekermann K, Wormann B, Sauerland MC, Heinecke A, Hiddemann W, Hehlmann R, Buchner T. 2009. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG. Leukemia 23: 2248-2258.
15. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F. 2010. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group. Blood 116: 3171-3179.
16. Manola KN, Karakosta M, Sambani C, Terzoudi G, Pagoni M, Gatsa E, Papaioannou M. 2010. Isochromosome der(17)(q10)t(15;17) in acute promyelocytic leukemia resulting in an additional copy of the RARA-PML fusion gene: Report of 4 cases and review of the literature. Acta Haematol 123: 162-170.
17. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. 2008. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1919-1928.
18. Mullighan CG, Downing JR. 2009. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: Recent insights and future directions. Leukemia 23: 1209-1218.
19. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR. 2009. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360: 470-480.
20. Nowak D, Hofmann WK, Koeffler HP. 2009a. Genome-wide mapping of copy number variations using SNP arrays. Transfus Med Hemother 36: 246-251.
21. Nowak D, Le Toriellec E, Stern MH, Kawamata N, Akagi T, Dyer MJ, Hofmann WK, Ogawa S, Koeffler HP. 2009b. Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica 94: 518-527.
22. Nowak D, Ogawa S, Muschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. 2010. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 115: 1049-1053.
23. Parkin B, Erba H, Ouillette P, Roulston D, Purkayastha A, Karp J, Talpaz M, Kujawski L, Shakhan S, Li C, Shedden K, Malek SN. 2010. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood 20: 20.
24. Rowley JD, Golomb HM, Dougherty C. 1977. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1: 549-550.
25. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Buchner T, Dohner H, Burnett AK, Lo-Coco F. 2009. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113: 1875-1891.
26. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Diaz-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F. 2000. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96: 1247-1253.
27. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Roman J, Barragan E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P. 2004. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 103: 1237-1243.
28. Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, Gonzalez J, Diaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, Gonzalez JD, Lowenberg B. 2010. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome. Blood 115: 5137-5146.
29. Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O'Gara BP, Bloomfield CD, Mrozek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ. 2009. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA 106: 12950-12955.
30. Walz C, Grimwade D, Saussele S, Lengfelder E, Haferlach C, Schnittger S, Lafage-Pochitaloff M, Hochhaus A, Cross NC, Reiter A. 2010. Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia. Genes Chromosomes Cancer 49: 471-479.
31. Wang ZY, Chen Z. 2008. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111: 2505-2515.
32. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A, Kurokawa M, Chiba S, Gilliland DG, Koeffler HP, Ogawa S. 2007. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81: 114-126.